Claims

1. A composition, which comprises a pharmaceutically acceptable salt of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, a cosolvent, and a surfactant.
2. A composition according to claim 1, which further comprises water.
3. A composition according to claim 2, which is in the form of a solution.
4. A composition according to claim 3, in which the cosolvent is a member, selected from the group, consisting of propylene glycol, polyethylene glycol 400 and glycerin.
5. A composition according to claim 3, in which the surfactant is a member, selected from the group, consisting of a polysorbate, a polyoxypropylene-polyoxyethylene block copolymer and a polyethoxylated castor oil.
6. A composition according to claim 3, which further comprises an antioxidant.
7. A composition according to claim 6, in which the antioxidant is a member, selected from the group, consisting of ascorbic acid, a tocopherol, sodium sulfite, sodium metabisulfite, glutathione, thiourea, L-cysteine hydrochloride monohydrate, N-acetylcysteine and a monothioglycerol.
8. A composition according to claim 6, which further comprises a buffer.
9. A composition according to claim 8, in which the buffer is a member, selected from the group, consisting of a glycine buffer and a phosphate buffer.
10. A composition according to claim 8, in which the pharmaceutically acceptable salt of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid is the potassium salt.
11. A composition according to claim 10, in which the cosolvent is polyethylene glycol 400.
12. A composition according to claim 11, in which the surfactant is a polysorbate.
13. A composition according to claim 12, in which the antioxidant is a monothioglycerol.
14. A composition according to claim 13, in which the buffer is a glycine buffer.
15. A composition according to claim 14, which further comprises a glass container, selected from the group, consisting of a vial and an ampoule.
16. A composition according to claim 15, characterized in that the solution is disposed in the glass container.
17. A method for minimizing the chemical degradation of the potassium salt of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid in an aqueous solution

comprising the said salt, which method comprises adjusting the pH value of the aqueous solution to between about 8.5 and about 10.5.

18. A method for increasing the local tolerance while parenterally administering a composition comprising the potassium salt of 5-methyl-2-(2'-chloro-6'-fluoro-anilino)phenylacetic acid, which method comprises administering the said salt in the form of an aqueous solution that also comprises a cosolvent.

19. A method according to claim 18, characterized in that the cosolvent is polyethylene glycol 400.

20. A method for the treatment of a cyclooxygenase-2-mediated disorder or condition, which comprises parenterally administering a composition according to claim 1.

21. A method according to claim 20, which comprises parenterally administering a composition according to claim 14.